Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Clinical Trials Report for June 2015

    ... intensity conditioning regimen to allow successful engraftment with CD3+ /CD19+ depleted peripheral stem cell grafts from ...

    Page last updated 06/18/2015 - 11:47am.

  2. Clinical Trials Report for May 2015

    ... intensity conditioning regimen to allow successful engraftment with CD3+ /CD19+ depleted peripheral stem cell grafts from ...

    Page last updated 04/28/2015 - 11:38am.

  3. Clinical Trials Report for April 2015

    ... intensity conditioning regimen to allow successful engraftment with CD3+ /CD19+ depleted peripheral stem cell grafts from ...

    Page last updated 03/30/2015 - 11:40am.

  4. Clinical Trials Report for March 2015

    ... intensity conditioning regimen to allow successful engraftment with CD3+ /CD19+ depleted peripheral stem cell grafts from ...

    Page last updated 03/02/2015 - 10:06am.

  5. CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease

    ... with malignant and non-malignant disease with successful engraftment and has shown some improvement in GVHD. It is unknown if CD34+ ...

    Clinical Trial last updated 04/27/2016 - 8:55am.

  6. The Transplantation Procedure

    ... of immune suppression prior to SCT in order to allow for engraftment of donor stem cells .  To prepare for the transplant, ... healthy blood cells your body needs. This process is called engraftment and may take two to three or even four weeks. Until the donor cells ...

    Page last updated 05/14/2015 - 10:39am.

  7. Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

    ... percent or if the combined event rate for failed donor engraftment or treatment related mortality (TRM) at day 100 exceeds 20 ... Secondary end points include transplant related mortality, engraftment, degree of donor-host chimerism, incidence of acute and chronic ...

    Clinical Trial last updated 04/25/2016 - 10:08am.

  8. Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

    ... percent or if the combined event rate for failed donor engraftment or treatment related mortality (TRM) at day 100 exceeds 20 ... Secondary end points include transplant related mortality, engraftment, degree of donor-host chimerism, incidence of acute and chronic ...

    Clinical Trial last updated 04/28/2016 - 2:40pm.

  9. Transplants With Unlicensed Preserved Cord Blood

    ... incidence of chronic GVHD Determine CBU-derived engraftment Eligibility Criteria Inclusion Criteria ...

    Clinical Trial last updated 04/27/2016 - 3:20pm.

  10. Transplantation Update

    ... omit cyclophosphamide because there was failure of engraftment when this drug was not used.  However, smaller doses (50 or ...

    Interview last updated 05/14/2015 - 2:42pm.